124276-63-7

Basic information

• Product Name: 1-(2-TRIFLUOROMETHYL-PHENYL)-CYCLOPROPANECARBONITRILE
• Synonyms: 1-(2-TRIFLUOROMETHYL-PHENYL)-CYCLOPROPANECARBONITRILE
• CAS NO: 124276-63-7
• Molecular Formula: C₁₁H₈F₃N
• Molecular Weight: 211.1831296
• Mol File: 124276-63-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 278.6±40.0 °C(Predicted)
• Appearance: /
• Density: 1.29±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-(2-TRIFLUOROMETHYL-PHENYL)-CYCLOPROPANECARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-TRIFLUOROMETHYL-PHENYL)-CYCLOPROPANECARBONITRILE(124276-63-7)
• EPA Substance Registry System: 1-(2-TRIFLUOROMETHYL-PHENYL)-CYCLOPROPANECARBONITRILE(124276-63-7)

Safety Data

• Hazardous Substances Data: 124276-63-7(Hazardous Substances Data)

Usage

General Description

1-(2-trifluoromethyl-phenyl)-cyclopropanecarbonitrile is a chemical compound with the molecular formula C11H7F3N. It is a nitrile derivative with a unique cyclopropane ring and a trifluoromethylphenyl group. 1-(2-TRIFLUOROMETHYL-PHENYL)-CYCLOPROPANECARBONITRILE is used in the synthesis of various pharmaceuticals and agrochemicals, as well as in the development of advanced materials. It has potential applications in the field of medicinal chemistry due to its structural features and reactivity. Additionally, it can be used as a building block in organic synthesis for the creation of novel chemical compounds.

Upstream product

• 3038-47-9 2-(trifluoromethyl)phenylacetonitrile 
• 107-04-0 1-Bromo-2-chloroethane 

Downstream Products

• 886366-06-9 1-[2-(trifluoromethyl)phenyl]cyclopropanecarboxylic acid 
• 1067188-03-7 2-oxo-2-(1-(2-(trifluoromethyl)phenyl)cyclopropyl)ethyl acetate 
• 1067188-02-6 2-chloro-1-(1-(2-(trifluoromethyl)phenyl)cyclopropyl)ethanone 

Relevant articles and documents

COMPOUNDS FOR TREATING AND PREVENTING GROWTH HORMONE RECEPTOR-DEPENDENT CONDITIONS

The invention relates to compounds, in particular pyrimidine-2,4-diamines, analogues and salts thereof and pharmaceutical compositions comprising pyrimidine-2,4-diamines analogues and salts thereof for use in the treatment and prevention of a disease, in particular a growth hormone receptor-dependent condition. The invention also relates to methods of using these compounds and compositions to treat physiological dsorders related to the amount or activity of growth hormone. In a particular embodiment, the invention relates to a compound according to formula 1 for use in the treatment or prevention of a disease in a subject

NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.